Abstract 175P
Background
Cancer cells evade the human immune system by manipulating the tumor-immune microenvironment (TIME) via suppressing the immuno-activator and promoting the immune-suppressive mediators. Hence, targeting immuno-modulatory factors became an ingenious treatment option, particularly for cancer types that shows scarcity of treatment options such as triple negative breast cancer (TNBC). Novel immuno-modulatory targets such as Galectin (GAL) 3 and 9 have been found to be overexpressed in TNBC, repressing the immune surveillance. Similarly, TNBC tumors were found to prevent the activation of immune infiltrating lymphocytes via overexpressing immune checkpoint CD155 expression on its surface. MHC class I polypeptide–related sequence A (MICA) and MICB are stress-induced ligands essential for innate immunity activation at the TIME. However, their expression is also often suppressed in TNBC, leading to immune suppression and poor prognosis. Our research group has extensively worked on microRNAs to modulate multiple targets simultaneously. Hence, this work unravels the expression profile of the miR-548c in BC tissues, evaluate its unprecedented immunomodulatory role in TNBC via altering GAL3/9, CD155, and MICA/B expression.
Methods
BC female patients (n=20) were recruited. In-silico analysis was used to identify miRNAs that target immunomodulatory targets. MDA-MB-231 TNBC cells were cultured and transfected by oligonucleotides. Total RNA was extracted using Biazol, reverse transcribed and quantified using qRT-PCR.
Results
miRNA-548c is a down-regulated tumor suppressor miRNA in BC tissues compared to its normal counterparts. MiRNA-548c was validated to regulate the immunogenic profile in TNBC. Given the overexpression of the immuno-suppressive GAL3, GAL9, and CD155, miR-548c simultaneously constrained their expression in TNBC cells. Moreover, ectopic expression of miR-548c in MDA-MB-231 cells resulted in a marked upregulation of the expression of the immuno-activators MICA and MICB, enhancing the overall immunogenic profile of TNBC cells.
Conclusions
This study identifies miRNA-548c as a booster of the immune surveillance by concomitant adjustment for the immunogenic ligands expressed/produced by the TNBC cell.
Legal entity responsible for the study
The authors.
Funding
This work was supported by Swiss National Science Foundation (SNSF), grant IZSTZ0_198887.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
169P - High-dimensional analysis of tumor infiltrating immune cells reveals major differences in the tumor immune microenvironments of pleural mesothelioma and lung cancer
Presenter: Angelica Rigutto
Session: Poster Display
170P - Targeting myeloid cells in non-small cell lung cancer and hepatocellular carcinoma: a window-of-opportunity trial of nivolumab with BMS-813160 (CCR2/5i) or BMS-986253 (anti-IL8)
Presenter: Nicholas Venturini
Session: Poster Display
171P - Immune landscape and CLEVER-1 expression in hepatoblastoma
Presenter: Ville Väyrynen
Session: Poster Display
172P - PLCE1 stabilizes ENO1 to enhance glycolysis in esophageal squamous cell carcinoma (ESCC) and induces an immune-suppressive tumor microenvironment
Presenter: Ju Yang
Session: Poster Display
173P - Depleting resident peritoneal macrophages is an effective treatment for peritoneal metastasized colorectal cancer
Presenter: Job Saris
Session: Poster Display
174P - Targeting SPHK1 in macrophages suppresses liver metastasis of colorectal cancer and decouples anti-tumor immunity from immunotherapy toxicity
Presenter: Yizhi Zhan
Session: Poster Display
176P - Multiplex-immunoflourescence spatial patterns to predict triple-negative breast cancer molecular subtypes in the IMMUcan study
Presenter: Andrea Joaquin Garcia
Session: Poster Display
177P - The Immune-microenvironment Confers Chemoresistance in Breast cancer through activation of VEGFR2/STAT3/BIRC5 signaling
Presenter: Bhawna Deswal
Session: Poster Display
178P - Dynamics of breast cancer T cell repertoire during neoadjuvant chemotherapy / immunotherapy.
Presenter: Charlotte Birchall
Session: Poster Display
179P - Integrating multiplex immunofluorescence with gene expression data in the IMMUcan HER2-positive breast cancer cohort
Presenter: Mattia Rediti
Session: Poster Display